Terlipressin acetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318850

CAS#: 914453-96-6 (acetate)

Description: Terlipressin is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Indications for use include norepinephrine-resistant septic shock and hepatorenal syndrome. In addition, it is used to treat bleeding esophageal varices. Terlipressin is currently not available in the United States, or Canada, but it is available in New Zealand, Australia, much of Europe, India & UAE.

Chemical Structure

Terlipressin acetate
CAS# 914453-96-6 (acetate)

Theoretical Analysis

MedKoo Cat#: 318850
Name: Terlipressin acetate
CAS#: 914453-96-6 (acetate)
Chemical Formula: C54H78N16O17S2
Exact Mass:
Molecular Weight: 1287.433
Elemental Analysis: C, 50.38; H, 6.11; N, 17.41; O, 21.13; S, 4.98

Price and Availability

Size Price Availability Quantity
1.0g USD 1650.0 2 Weeks
2.0g USD 2950.0 2 Weeks
5.0g USD 3950.0 2 Weeks
10.0g USD 5950.0 2 Weeks
20.0g USD 8950.0 2 Weeks
Bulk inquiry

Related CAS #: 914453-96-6 (acetate)   14636-12-5 (acetate)   14636-12-5 (free base)  

Synonym: TGLVP; triglycyl lysine vasopressin; Gly-Gly-Gly-8-Lys-vasopressin; Terlipressin; Terlipressin acetate; trade names Teripress, Glypressin.

IUPAC/Chemical Name: 1-{[(4R,7S,10S,13S,16S,19R)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-N-(2-amino-2-oxoethyl)-L-lysinamide acetate


InChi Code: InChI=1S/C52H74N16O15S2.C2H4O2/c53-17-5-4-9-37(45(58)76)68(25-41(57)72)52(83)38-10-6-18-67(38)51(82)36-27-85-84-26-35(61-44(75)24-60-43(74)23-59-42(73)22-54)50(81)64-33(20-29-11-13-30(69)14-12-29)48(79)63-32(19-28-7-2-1-3-8-28)47(78)62-31(15-16-39(55)70)46(77)65-34(21-40(56)71)49(80)66-36;1-2(3)4/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H2,58,76)(H,59,73)(H,60,74)(H,61,75)(H,62,78)(H,63,79)(H,64,81)(H,65,77)(H,66,80);1H3,(H,3,4)/t31-,32-,33-,34-,35-,36-,37-,38-;/m0./s1

SMILES Code: NCCCC[C@@H](C(N)=O)N(C([C@H]1N(C([C@@H](NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)=O)=O)=O)CSSC[C@H](NC(CNC(CNC(CN)=O)=O)=O)C4=O)=O)CCC1)=O)CC(N)=O.CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1287.433 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Huang Y, Wang M, Wang J. Hyponatraemia induced by terlipressin: a case report and literature review. J Clin Pharm Ther. 2015 Nov 17. doi: 10.1111/jcpt.12335. [Epub ahead of print] Review. PubMed PMID: 26573870.

2: Taşliyurt T, Kutlutürk F, Erdemır F, Yelken BM, Yilmaz A, Kisacik B, Aytan P, Köseoğlu RD. Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature. Turk J Gastroenterol. 2012;23(6):788-91. Review. PubMed PMID: 23864457.

3: Solà E, Cárdenas A, Ginès P. Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Curr Opin Organ Transplant. 2013 Jun;18(3):265-70. doi: 10.1097/MOT.0b013e3283614c7a. Review. PubMed PMID: 23652609.

4: Biban P, Gaffuri M. Vasopressin and terlipressin in neonates and children with refractory septic shock. Curr Drug Metab. 2013 Feb;14(2):186-92. Review. PubMed PMID: 23439212.

5: Piazza O, Scarpati G, Rispoli F, Iannuzzi M, Tufano R, De Robertis E. Terlipressin in brain-death donors. Clin Transplant. 2012 Nov-Dec;26(6):E571-5. doi: 10.1111/ctr.12038. Epub 2012 Nov 2. Review. PubMed PMID: 23121213.

6: Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012 Sep 12;9:CD005162. doi: 10.1002/14651858.CD005162.pub3. Review. PubMed PMID: 22972083.

7: Serpa Neto A, Nassar AP, Cardoso SO, Manetta JA, Pereira VG, Espósito DC, Damasceno MC, Russell JA. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012 Aug 14;16(4):R154. doi: 10.1186/cc11469. Review. PubMed PMID: 22889256; PubMed Central PMCID: PMC3580743.

8: Mazur JE, Cooper TB, Dasta JF. Terlipressin in hepatorenal syndrome. Ann Pharmacother. 2011 Mar;45(3):380-7. doi: 10.1345/aph.1P195. Epub 2011 Mar 8. Review. PubMed PMID: 21386023.

9: Meyer S, McGuire W, Gottschling S, Mohammed Shamdeen G, Gortner L. The role of vasopressin and terlipressin in catecholamine-resistant shock and cardio-circulatory arrest in children: review of the literature. Wien Med Wochenschr. 2011 Apr;161(7-8):192-203. doi: 10.1007/s10354-010-0853-7. Epub 2011 Jan 25. Review. PubMed PMID: 21253815.

10: Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: Evidence for present indications. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review. PubMed PMID: 21199521.

11: Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol. 2010 Nov 7;16(41):5139-47. Review. PubMed PMID: 21049548; PubMed Central PMCID: PMC2975085.

12: Elzouki AN, El-Menyar A, Ahmed E, Elbadri ME, Imam YZ, Gurbanna BA. Terlipressin-induced severe left and right ventricular dysfunction in patient presented with upper gastrointestinal bleeding: case report and literature review. Am J Emerg Med. 2010 May;28(4):540.e1-6. doi: 10.1016/j.ajem.2009.08.012. Epub 2010 Mar 12. Review. PubMed PMID: 20466263.

13: Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol. 2011 Mar;43(1):175-84. doi: 10.1007/s11255-010-9725-8. Epub 2010 Mar 20. Review. PubMed PMID: 20306131; PubMed Central PMCID: PMC3881971.

14: Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010 May;25(5):880-5. doi: 10.1111/j.1440-1746.2009.06132.x. Epub 2010 Jan 14. Review. PubMed PMID: 20074149.

15: Morelli A, Ertmer C, Pietropaoli P, Westphal M. Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock. Expert Opin Pharmacother. 2009 Oct;10(15):2569-75. doi: 10.1517/14656560903257808. Review. PubMed PMID: 19735216.

16: Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials. Int J Artif Organs. 2009 Mar;32(3):133-40. Review. PubMed PMID: 19440988.

17: Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007 Dec;1(2):207-17. doi: 10.1586/17474124.1.2.207. Review. PubMed PMID: 19072411.

18: Krag A, Borup T, Møller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther. 2008 Nov;25(11):1105-40. doi: 10.1007/s12325-008-0118-7. Review. PubMed PMID: 19018483.

19: Singer M. Arginine vasopressin vs. terlipressin in the treatment of shock states. Best Pract Res Clin Anaesthesiol. 2008 Jun;22(2):359-68. Review. PubMed PMID: 18683481.

20: Leone M, Martin C. Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock. Best Pract Res Clin Anaesthesiol. 2008 Jun;22(2):323-33. Review. PubMed PMID: 18683478.